[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-diagnosis":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,44,69,95,126,149,179,203,230,261,288,311,341,367,405,438,459,483,504,525,550,576,604,637,659],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100652977","creation-of-a-biological-collection-of-bronchiai-and-pulmonary-tissues-from-surgical-waste-100652977",false,"NCT07780630","Creation of a Biological Collection of BRonchiaI and Pulmonary Tissues From Surgical wastE","BRISE","Inclusion Criteria:\n\n* Male or female\n* Adult or children\n* Having required or necessitating, in the context of care or research involving the human person promoted by the Bordeaux University Hospital (ARISE, BIRDIES, ICEBERG, VIRCHILLD) or by Inserm (COBRA), either thoracic surgery such as lobectomy, pneumonectomy or lung transplantation in the Thoracic Surgery Department of the Haut Lévêque Hospital, or bronchial fiberscopy with biopsies and\u002For bronchial brushing and\u002For BAL at the children's hospital of the Pellegrin Hospital or at the Haut Lévêque Hospital.\n* Having received or, for children whose holders of parental authority have received, an information note with the possibility of opposition in accordance with the MR004 (French law - Commission Nationale de l'Informatique et des Libertés (CNIL))\n\nExclusion Criteria:\n\n* Patient or holder of parental authority for children who have expressed their opposition to participation in the research",true,"ALL","1 Year","80 Years",{"count":22,"type":23},650,"ESTIMATED","1 Day","OBSERVATIONAL","The biological samples and associated data will facilitate the successful implementation of the research collaboration between Bordeaux University Hospital and the University of Bordeaux on the pathophysiology of bronchopulmonary diseases. In the longer term, this research could lead to the discovery of new therapeutic targets for asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, and acute respiratory distress syndrome.",[28,29,30],"COPD (Chronic Obstructive Pulmonary Disease)","Asthma (Diagnosis)","Safe Volunteers","NOT_YET_RECRUITING","2026-08-19",{"date":34,"type":35},"2026-08-21","ACTUAL",{"date":37,"type":23},"2026-09-01",{"date":39,"type":23},"2028-12-31",{"name":41,"class":42},"University Hospital, Bordeaux","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":67,"locationsCount":4},"100652275","respiratory-admittance-by-oscillometry-in-children-100652275","NCT07771608","Respiratory Admittance by Oscillometry in Children","Respiratory Admittance Response to Exercise Challenge Test in Children","ArsEIB","Inclusion Criteria:\n\n* Children aged 5 to 16 years\n* Children addressed by the pediatric pulmonologist to an exercise challenge test between January 2023 and April 2026\n* Children with interpretable and reproducible oscillometric measurements\n* Children with interpretable and reproducible spirometric measurements\n\nExclusion Criteria:\n\n* Children who performed only spirometric measurements\n* Children who performed only oscillometric measurements\n* Children whose oscillometric and spirometric measurements are non-interpretable\n* Children whose oscillometric and spirometric measurements are non-reproducible","5 Years","16 Years",{"count":55,"type":23},144,"Oscillometry is a pulmonary function testing technique suited for children because it does not require specific respiratory maneuvers like spirometry. Oscillometry provides a measure of respiratory impedance (Zrs) that is underestimated when the oscillatory signal is applied at the subject's mouth particularly during bronchoconstriction induced by an exercise challenge test (ECT). This limitation may be overcome by calculating respiratory admittance (Ars), the inverse of respiratory impedance during an ECT.",[29],[59,60,61],"lung function testing","oscillometry","asthma","2026-08-17",{"date":32,"type":35},{"date":65,"type":23},"2026-08-25",{"date":37,"type":23},{"name":68,"class":42},"Central Hospital, Nancy, France",{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":43},"100651955","phase-3-beclometasone-dipropionate-and-formoterol-inhalation-aerosol-for-asthma-100651955","NCT07768891","Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma","A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Phase III Clinical Study Comparing the Efficacy and Safety of Beclometasone Dipropionate and Formoterol Inhalation Aerosol Versus FOSTER® in Patients With Asthma.","Inclusion Criteria:\n\n1. Male or female aged ≥18 and ≤75 years.\n2. Clinically diagnosed with bronchial asthma for at least 3 months at screening (with traceable diagnostic evidence and medical records), and the diagnosis has been confirmed according to the Guidelines for the Prevention and Management of Bronchial Asthma, meeting the following criteria:\n\n   a) Positive objective test for variable airflow limitation (i.e., meeting any one of the following): (i) Positive bronchodilator reversibility test (i.e., an increase in FEV₁ of ≥12% and an absolute increase of ≥200 mL from pre-bronchodilator values after inhalation of a bronchodilator; or an increase in FEV₁ of ≥12% and an absolute increase of ≥200 mL from baseline after 4 weeks of anti-inflammatory therapy with an inhaled corticosteroid, excluding respiratory tract infections); or (ii) Positive bronchial provocation test: commonly using methacholine or histamine as the inhaled provocative agent, with a positive result defined as a ≥20% decrease in FEV₁ after inhalation, indicating airway hyperresponsiveness. (A positive result from any confirmed objective test for variable airflow limitation performed within 1 year prior to signing the ICF is acceptable; if not available, a positive bronchial provocation or bronchodilator reversibility test must be met at screening.) b) Pulmonary function test: FEV₁ ≥40% of predicted value.\n3. Within at least 4 weeks prior to signing the ICF, the subject has been on a stable daily dose of an inhaled corticosteroid (ICS) with \"as-needed\" short-acting β₂-agonist (SABA) use but asthma is not well controlled (ACQ-5 ≥1.00), OR has been on a stable daily dose of an ICS plus a long-acting β₂-agonist (LABA) and asthma is well controlled (ACQ-5 \\\u003C1.00).\n4. Subjects who use SABA or other reliever medications as needed before screening may be enrolled only if the investigator assesses that they can be switched to the unified rescue medication provided in this study.\n5. Willing and able to comply with the protocol requirements and the investigator's instructions for pulmonary function tests, and, after training, able to correctly use the pressurized metered-dose inhaler (pMDI), peak flow meter, and complete the diary card records.\n6. Willing to voluntarily participate in this study and sign the informed consent form after full informed consent.\n\nExclusion Criteria:\n\n1. Have intermittent asthma or asthma that occurs only upon occasional exposure to allergens or chemical sensitizers.\n2. Have a history of life-threatening asthma (e.g., brittle asthma, admission to the intensive care unit due to an acute asthma exacerbation) within 1 year prior to screening.\n3. Have other respiratory system diseases, including but not limited to allergic bronchopulmonary aspergillosis (ABPA), active tuberculosis, pneumonia, pneumothorax, idiopathic pulmonary fibrosis, clinically significant atelectasis, chronic obstructive pulmonary disease (COPD), bronchopulmonary dysplasia, chronic bronchitis, or other significant pulmonary abnormalities other than asthma (such as cystic fibrosis, bronchiectasis, or alpha-1 antitrypsin deficiency), and are considered by the investigator to be unsuitable for participation in this clinical study.\n4. Have a respiratory tract infection of non-viral etiology, sinusitis, or otitis media within 4 weeks prior to screening.\n5. Have a history of severe cardiovascular or cerebrovascular diseases, such as congestive heart failure of New York Heart Association (NYHA) class ≥II, unstable angina, coronary heart disease, myocardial infarction, stroke, etc., within 6 months prior to screening; have a prolonged QTc interval (QTc \\>450 ms for males or \\>470 ms for females, corrected using Fridericia's formula) or have ECG abnormalities that are assessed by the investigator as clinically significant and requiring pharmacological treatment; or have poorly controlled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg after adequate treatment).\n6. Have oral candidiasis identified at screening.\n7. Have laboratory test results meeting any of the following criteria: Liver function: alanine aminotransferase (ALT) \\>2×ULN and\u002For aspartate aminotransferase (AST) \\>2×ULN, and total bilirubin (TBIL) \\>2×ULN; Renal function: serum creatinine \\>1.5×ULN; Fasting blood glucose \\>10 mmol\u002FL or glycated hemoglobin (HbA1c) ≥8.0%; Serum potassium \\\u003C3.5 mmol\u002FL.\n8. Have received biological targeted therapy (including anti-IgE monoclonal antibodies such as omalizumab, anti-IL-5 monoclonal antibodies such as mepolizumab, anti-IL-5 receptor monoclonal antibodies such as benralizumab, or anti-IL-4 receptor monoclonal antibodies such as dupilumab) within 5 half-lives prior to entry into the run-in period.\n9. Have experienced an asthma exacerbation requiring systemic corticosteroid treatment or have required oral corticosteroid therapy within 4 weeks prior to screening, or have other diseases that require long-term oral or intravenous corticosteroid therapy.\n10. Have used beta-blockers (including eye drops), quinidine, disopyramide, procainamide, phenothiazines, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, or any other medications that may prolong the QTc interval and increase the risk of ventricular arrhythmias within 4 weeks prior to screening.\n11. Have a history of drug abuse or alcohol abuse within 1 year prior to screening.\n12. Are current smokers; have a smoking history of ≥10 pack-years (1 pack = 20 cigarettes); for those with a smoking history of \\\u003C10 pack-years, they must have stopped smoking for at least 6 months to be eligible for the study.\n13. Have received treatment with any other investigational drug or device in another clinical trial within 3 months prior to screening.\n14. Have a known intolerance to or contraindication to beta₂-agonists and\u002For inhaled corticosteroids, or are allergic to any component of the investigational products.\n15. Are pregnant or breastfeeding; or are women of childbearing potential, or male subjects with partners of childbearing potential, who do not agree to use medically recognized effective contraceptive measures (such as an intrauterine device or condom) during the study and for 6 months after the last dose of the investigational product.\n16. Meet any of the following conditions prior to randomization:\n\n    1. Run-in period compliance \\\u003C80% or \\>120%;\n    2. Have an asthma exacerbation during the run-in period (including asthma-related serious adverse events, asthma worsening leading to hospitalization or emergency treatment, unscheduled visits resulting in changes in treatment, etc.);\n    3. Are considered by the investigator to be unsuitable for randomization.","18 Years","75 Years",{"count":79,"type":23},416,"INTERVENTIONAL",[82],"PHASE3","A multicenter, randomized, double-blind, active-controlled, parallel-group Phase III clinical study comparing the efficacy and safety of Beclometasone Dipropionate and Formoterol Inhalation Aerosol versus FOSTER® in patients with asthma. The purpose of this study is to compare the efficacy and safety of the Beclomethasone Dipropionate and Formoterol Fumarate inhalation aerosol (manufactured by Lunan Better Pharmaceutical Co., Ltd.) with FOSTER® in the treatment of patients with asthma.",[29],"RECRUITING","2026-08-12",{"date":62,"type":35},{"date":89,"type":35},"2026-06-08",{"date":91,"type":23},"2028-06",{"name":93,"class":94},"Lunan Better Pharmaceutical Co., LTD.","INDUSTRY",{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":18,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":80,"phases":107,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":43},"100627958","phase-2-pediatric-asthma-trial-of-corticosteroid-heterogeneity-patch-trial-of-dexamethasone-versus-methylprednisolone-for-pediatric-critical-asthma-100627958","NCT07455396","Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma","Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): A Phase 2 Prospective Randomized Open Blinded End-point (PROBE) Design, Randomized Clinical Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma","PATCH","Inclusion Criteria:\n\n* Age 3-17 years\n* Intensive care unit admission\n* Treatment for critical asthma\n\nExclusion Criteria:\n\n* History of unrepaired critical congenital heart disease\n* History of cystic fibrosis\n* Active tracheostomy dependence","3 Years","17 Years",{"count":106,"type":23},159,[108],"PHASE2","Acute asthma exacerbation is caused by dysregulated pulmonary inflammatory pathways such that standard treatment includes prompt administration of exogenous systemic corticosteroids (SCs), but there remains an ongoing dialogue among the expert medical community regarding the superiority of specific SCs including dose, frequency of administration, route, and delivery. Regimens are often chosen based on provider preference, and different strategies include once-daily dosing (ODD) dexamethasone (DM) 0.6 mg\u002Fkg\u002Fdose for 2 days, every 6 hours (q6h) DM 0.25 mg\u002Fkg\u002Fdose for 2 days, and methylprednisolone (MP) 1 mg\u002Fkg\u002Fdose every 6 hours for 5-days.\n\nTo address this knowledge gap, the investigators plan to perform a single-center, phase 2, randomized clinical trial of children 3-17 years of age hospitalized for critical asthma (CA) randomized to one of three regimens above. The study would be powered to evaluate rates of additional prescriptions of SC and also secondarily evaluate quality of life metrics.",[29],[112,113,114,115,116,117],"pediatric critical asthma","pediatric intensive care unit","status asthmaticus","systemic corticosteroids","methylprednisolone","dexamethasone","2026-08-10",{"date":86,"type":35},{"date":121,"type":35},"2026-08-01",{"date":123,"type":23},"2028-08-14",{"name":125,"class":42},"Johns Hopkins All Children's Hospital",{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":80,"phases":135,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100649241","phase-1-a-randomized-phase-ib-double-blind-placebo-controlled-study-to-evaluate-the-safety-and-efficacy-of-skb575-hbm7575-in-participants-with-asthma-100649241","NCT07732023","A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma","Inclusion Criteria:\n\n1. The participant is able to understand and comply with the requirements of this study, and voluntarily signs the informed consent form.\n2. Aged between 18 and 70 years inclusive at the time of signing the informed consent form, with no restriction on gender.\n3. Body Mass Index (BMI) shall be ≥ 18.0 kg\u002Fm² and ≤ 32.0 kg\u002Fm².\n4. Diagnosis of asthma consistent with the Global Initiative for Asthma (GINA) 2025 diagnostic criteria.\n5. Pulmonary function test during the screening period must meet either of the following criteria: After albuterol inhalation, the forced expiratory volume in one second (FEV₁) increases by ≥ 12% with an absolute FEV₁ increment of ≥ 200 mL; or the participant has a positive result from a bronchodilator reversibility test or bronchial provocation test within the past 12 months.\n6. Participants must have received a stable dose of controller medication for a minimum of 3 months prior to randomization. Subjects shall be on maintenance therapy with low-, medium- or high-dose inhaled corticosteroids (ICS), which may be combined with other asthma controller medications including long-acting beta₂ agonists (LABA), long-acting muscarinic antagonists (LAMA), and leukotriene receptor antagonists (LTRA). The treatment regimen and dosage shall remain unchanged throughout the study period.\n7. Pre-bronchodilator forced expiratory volume in one second (FEV₁) ≥ 50% of predicted value during screening.\n8. Male and female participants must agree to use highly effective contraceptive methods for the specified duration of the study.\n\nExclusion Criteria:\n\n1. Within 3 months prior to randomization, the participant experienced an acute asthma exacerbation requiring continuous systemic corticosteroid therapy for ≥3 consecutive days, or presented to the emergency department or was hospitalized due to asthma with administration of systemic corticosteroids (calculated from the completion date of treatment for the asthma exacerbation).\n2. Known hypersensitivity to the investigational product or its excipients, or a history of allergic reactions to any biological products.\n3. Concomitant clinically significant pulmonary diseases, including but not limited to pulmonary infection, chronic obstructive pulmonary disease (COPD), bronchiectasis, interstitial lung disease, pulmonary vascular disease, pulmonary neoplasm, or any other diseases affecting pulmonary function other than asthma.\n4. Concomitant diseases that may impair pulmonary function, including but not limited to clinically significant pleural disorders, mediastinal diseases, diaphragmatic lesions, myasthenia, thoracic deformities, etc.\n5. Concomitant autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis, primary biliary cholangitis, etc.\n6. Known or suspected history of immunosuppression, including a history of invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis and aspergillosis), even if the infection has resolved.\n7. Confirmed parasitic infection within 6 months prior to randomization; upper or lower respiratory tract infection occurring within 6 weeks prior to randomization; other active infections requiring systemic treatment identified within 1 month prior to randomization.\n8. Previous history of malignant neoplasm, regardless of whether treatment was administered, or whether there is evidence of local recurrence or metastasis.\n9. Presence of any history of severe clinically significant diseases involving cardiovascular and cerebrovascular systems, hematological system, liver, kidney, digestive tract, nervous system, respiratory system, psychiatric disorders, metabolic abnormalities, or any other diseases or physiological conditions that may interfere with the trial results.\n10. Participants who have undergone or are planning to undergo major surgery within 3 months prior to randomization.\n11. Current smoker at screening, or having quit tobacco (including e-cigarettes) for less than 6 months.\n12. History of drug or alcohol abuse within 2 years prior to randomization.\n13. Female participants who are pregnant or breastfeeding.\n14. Any condition deemed by the investigator to interfere with the evaluation of the investigational product, compromise participant safety, or confound the interpretation of study results.","70 Years",{"count":134,"type":23},36,[136],"PHASE1","This study is a multicenter, randomized, double-blind, placebo-controlled phase Ib study to evaluate the safety, tolerability, efficacy, PK\u002FPD characteristics, and immunogenicity of SKB575 (HBM7575) injection in subjects with asthma.",[29],"2026-07-22",{"date":141,"type":35},"2026-07-28",{"date":143,"type":23},"2026-07-20",{"date":145,"type":23},"2028-07-30",{"name":147,"class":94},"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.",2,{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":18,"minAge":157,"maxAge":104,"enrollmentInfo":158,"targetDuration":4,"studyType":80,"phases":160,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":43},"100638953","vr-vs-treadmill-exercise-in-children-with-asthma-100638953","NCT07610447","VR vs Treadmill Exercise in Children With Asthma","Comparison of Treadmill and Virtual Reality-Based Aerobic Exercise Programs in Children With Asthma","VR-ASTHMA","Inclusion Criteria:\n\n* Children and adolescents aged between 10 and 17 years\n* Physician-diagnosed asthma according to Global Initiative for Asthma (GINA) criteria\n* Stable medical treatment for asthma\n* Ability to participate in an aerobic exercise program\n* Willingness of the participant and parent\u002Flegal guardian to provide informed consent\n\nExclusion Criteria:\n\n* Presence of orthopedic, neurological, cardiovascular, or systemic conditions limiting participation in exercise\n* Contraindications to virtual reality use (e.g., epilepsy, photosensitivity)\n* Participation in a structured exercise program within the previous month\n* Asthma exacerbation within the previous month\n* Obesity diagnosis","10 Years",{"count":159,"type":23},30,[161],"NA","This study aims to compare the effects of virtual reality-based aerobic exercise and treadmill-based aerobic exercise on functional capacity, pulmonary function, and clinical outcomes in children with asthma. Participants aged 10-17 years with physician-diagnosed asthma will be randomly assigned to either a virtual reality-based exercise group or a treadmill exercise group. Both groups will undergo supervised exercise training sessions twice a week for 8 weeks. Primary outcome will be the 6-Minute Walk Test. Secondary outcomes include pulmonary function, respiratory muscle strength, asthma control, quality of life, and exercise adherence.",[29],[165,166,167,168,169,170],"Virtual Reality","Asthma","Aerobic Exercise","Pediatric Pulmonology","Exercise Training","Treadmill",{"date":172,"type":35},"2026-07-21",{"date":174,"type":35},"2026-05-25",{"date":176,"type":23},"2027-05-10",{"name":178,"class":42},"Bezmialem Vakif University",{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":80,"phases":189,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":43},"100648137","comparison-of-box-breathing-and-rhythmic-breathing-techniques-in-patients-with-asthma-100648137","NCT07717476","Comparison of Box Breathing and Rhythmic Breathing Techniques in Patients With Asthma","Comparative Effects of Box and Rhythmic Breathing Techniques on Dyspnea, Pulmonary Functions, and Quality of Sleep Among Asthmatic Patients","BRAS","Inclusion Criteria:\n\n* Male and female patients diagnosed with asthma.\n* Age between 18 and 40 years.\n* Patients with mild to moderate asthma who are clinically stable.\n* Patients able to understand and follow breathing exercise instructions.\n* Patients willing to provide informed consent and participate in the study.\n\nExclusion Criteria:\n\n* Patients with severe or uncontrolled asthma.\n* Patients with acute asthma exacerbation during the study period.\n* Patients with other significant respiratory diseases (e.g., chronic obstructive pulmonary disease, pulmonary fibrosis).\n* Patients with severe cardiovascular, neurological, or musculoskeletal disorders that may interfere with participation.\n* Patients who are pregnant.\n* Patients unable to perform the breathing interventions or complete study assessments.\n* Patients participating in another structured respiratory rehabilitation or breathing exercise program.","40 Years",{"count":134,"type":23},[161],"Asthma is a chronic respiratory disease that can cause breathing difficulties, reduced lung function, and poor sleep quality. Breathing exercises are increasingly used as non-pharmacological interventions to improve respiratory symptoms and overall well-being in individuals with asthma.\n\nThis study aims to compare the effects of two breathing techniques, Box Breathing and Rhythmic Breathing, on dyspnea (breathlessness), pulmonary function, and quality of sleep in patients with asthma. Participants with asthma will be randomly assigned to receive either Box Breathing or Rhythmic Breathing exercises in addition to standard care. Both interventions will be performed three times per week for eight weeks.\n\nThe primary outcomes of this study include changes in dyspnea severity, pulmonary function measured by spirometry, and sleep quality assessed using validated questionnaires. The findings of this study may help determine which breathing technique is more effective and provide evidence for incorporating structured breathing exercises into asthma management programs.",[29],[166,193,194],"Box Breathing","Rhythmic Breathing","2026-07-17",{"date":172,"type":35},{"date":198,"type":23},"2026-07",{"date":200,"type":23},"2026-12-10",{"name":202,"class":42},"Riphah International University",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":80,"phases":214,"briefSummary":215,"conditions":216,"keywords":219,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":4},"100607667","phase-2-effect-of-linvemastat-in-patients-with-partially-controlled-asthma-symmponia-100607667","NCT07191535","Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)","A Multinational Randomized Double-Blind Placebo-Controlled Phase 2 Study to Evaluate the Effect of Linvemastat (FP-020) in Patients With Partially Controlled Asthma on Inhaled Corticosteroids and Long-Acting Beta-Agonists (syMMPonia Study)","syMMPonia","Inclusion Criteria:\n\n* Patients aged 18 - 85 years at the time of signing informed consent\n* Patient is able to provide written informed consent.\n* Documented physician´s diagnosis of Type 2 high asthma, as per the Global Initiative for Asthma (GINA) 2023 guideline 2023 at Screening.\n* Patients with existing treatment with at least low to medium doses of ICS therapy in combination with LABA as a second controller for at least 90 days and a stable\u002Foptimized dose ≥30 days prior to Day 1. Patients on triple therapy with a long-acting muscarinic antagonist (LAMA) will be excluded.\n* An ACQ score ≥ 1.5 at Screening.\n* Patients with a pre-bronchodilator FEV1 value of 40% to 80% of the patient's predicted value at Screening.\n* Patients must have experienced at least once, within 2 years prior to Screening, one of the following asthma exacerbation events: Treatment with a systemic steroid (oral or parenteral) for worsening asthma. Hospitalization or emergency medical care visit for worsening asthma.\n* Males with a partner of childbearing potential must use a condom for the duration of study treatment and at least 96 hours after discontinuing the study drug.\n* Female patients of childbearing potential (including those \\\u003C 1 year post-menopausal) must use a highly effective method of contraception per Clinical Trial Facilitation Group (CTFG) recommendation during the conduct of the study and for 30 days after the last dose of study drug. Highly effective contraceptive measures for female patients of childbearing potential include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal. Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable. intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (when partner is the sole sexual partner of the female patient and when the partner has received medical assessment of the surgical success), sexual abstinence.\n* Women not of childbearing potential are defined as: Post-menopausal women (defined as at least 12 months with no menses without an alternative medical cause); in women \\\u003C45 years of age, a high follicle-stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy; OR Have had a hysterectomy and\u002For bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation\u002Focclusion at least 6 weeks prior to Screening OR Have a congenital or acquired condition that prevents childbearing.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Current smoker (including vaping) or cessation of smoking within the 6 months prior to Day 1, or \\> 10 pack-year history of smoking.\n* Participation in another clinical trial of an investigational agent within 3 months (small molecule) \u002F 6 months (biologics) or 5 half-lives (if known) of the agent, whichever is longer, prior to randomization.\n* Evidence of COVID-19 infection at Screening, as judged by the Investigator.\n* Advanced congestive heart failure \\[New York Heart Association (NYHA) class 3 or 4\\].\n* Known hypersensitivity to any component of the formulation of linvemastat or any component of the excipient.\n* Live or messenger ribonucleic acid (mRNA) vaccination within 2 weeks before Day 1 or inoculation with a live or mRNA vaccine is planned during study participation.\n* History of solid organ transplant.\n* Anti-immunoglobulin E (IgE) therapy \\[e.g., omalizumab (Xolair®)\\] within 130 days prior to Screening or any other biologic therapy \\[including anti-TSLP, anti-IL-4\u002F4R or IL-5\u002F5R monoclonal antibodies (mAb)\\] or systemic immunosuppressant (e.g., methotrexate) to treat inflammatory disease or autoimmune disease (e.g., rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis) and other diseases, within 2 months or 5 half-lives prior to Screening, whichever is longer.\n* Evidence of active tuberculosis (TB) infection at Screening, as judged by the Investigator.\n* Active acute or chronic psychiatric illness that, in the opinion of the Investigator, may prevent from complying with study instructions.\n* Known positive history of malignancy within 5 years of Screening (with the exception of basal cell skin cancer, carcinoma in-situ of the cervix, or low-risk prostate cancer after curative therapy).\n* Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) infection at Screening.\n* Concurrent emphysema.\n* Use of any therapeutics that are strong inhibitors and inducers of CYP3A4 or CYP2C8 \\[e.g., rifampicin, ketoconazole, phenytoin, ritonavir, macrolide antibiotics (e.g., telithromycin), and carbamazepine\\].\n* History of liver dysfunction, including patients with moderate (Child-Pugh B) or severe (Child-Pugh C) impairment or disordered coagulation.\n* Abnormal ECG: ventricular arrhythmias (non-sustained ventricular tachycardia \\[VT\\], multifocal or frequent premature ventricular contractions, clinically significant bundle branch block or axis deviation \\[as assessed by PI\\], or abnormal Q waves). In the case of a corrected QT interval using Fridericia's formula (QTcF) interval \\>450 ms (men) or \\>480 ms (women; patients with bundle branch block) or PR (P to QRS) interval outside the range of 120 to 220 ms, the assessment may be repeated once for eligibility determination at Screening or Baseline.\n* Known uncontrolled hypertension or diabetes at the discretion of the Investigator.\n* Any condition that required hospitalization (except for asthma exacerbation) within the 3 months prior to Day 1 or is likely to require so during the study.\n* Clinically significant abnormalities in the Screening physical examination, medical history, vital signs, ECG, or clinical laboratory tests that are not known to be due to concurrent asthma in the opinion of the Investigator and Medical Monitor should preclude the patient's participation in the clinical study.\n* The following laboratory parameters are excluded:\n\n  1. Hemoglobin (Hg) \\\u003C10 g\u002FdL (100 g\u002FL)\n  2. White blood cells (WBC) \\\u003C 3000\u002FμL (\\\u003C 3000\u002Fmm3). African American patients who are known to have low WBC of \\\u003C 3000\u002FμL but ≥ 1500\u002FμL will be eligible.\n  3. Platelet count \\\u003C 70,000\u002FμL (70,000\u002Fmm3)\n  4. Serum creatinine \\> 1.5 x upper limit of normal (ULN)\n  5. Glomerular filtration rate ≤ 60 mL\u002Fmin\u002F1.73 m2 or evidence of acute kidney injury or history of severe hypersensitivity reactions to gadolinium-based contrast agents\n  6. Serum total bilirubin \\> 1.5 ULN\n  7. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2 x ULN or serum alkaline phosphatase \\> 2 x ULN","85 Years",{"count":213,"type":23},135,[108],"This study explores a potential new treatment for adults with moderate-to-severe asthma using a drug called linvemastat, which targets an enzyme linked to lung inflammation. Despite using standard asthma medications, many patients still struggle with symptoms, so researchers are testing whether linvemastat can improve lung function and reduce flare-ups. In a carefully controlled trial, participants receive either one of two doses of the drug or a placebo, while continuing their usual treatments. Over 16 weeks, scientists monitor breathing capacity, symptom control, and safety to determine if linvemastat could offer a meaningful new option for asthma management.",[29,217,218],"Pulmonary Function","Moderate-to-Severe Asthma",[220,221,222],"central spirometry","type-2 (T2) high asthma","asthma management",{"date":143,"type":35},{"date":225,"type":23},"2027-03-01",{"date":227,"type":23},"2028-09-01",{"name":229,"class":94},"Foresee Pharmaceuticals Co., Ltd.",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":80,"phases":240,"briefSummary":241,"conditions":242,"keywords":245,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":43},"100640560","phase-1-anakinra-rescue-treatment-for-moderate-asthma-attacks-artma-100640560","NCT07600190","Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)","Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA) Pilot Study","ARTMA","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Age ≥18 years\n* A history of physician-diagnosed persistent asthma or symptoms consistent with persistent asthma based on national or international guidelines for diagnosis and management of asthma.\n* Current use of controller therapy such as inhaled corticosteroid (ICS) or ICS in combination with long-acting beta agonist (LABA)\n* Asthma exacerbation requiring systemic corticosteroid therapy in the past 12 months\n* Negative pregnancy test for females who are not s\u002Fp hysterectomy with oophorectomy or who have been amenorrheic for 12 months or more.\n* Asthma Impairment and Risk Questionnaire (AIRQ) Score \\>2\n\nExclusion Criteria:\n\n* Clinical contraindications:\n\n  1. Physician diagnosis of other chronic pulmonary disease including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema or congenital disorders of the lungs or airways.\n  2. History of undergoing bronchial thermoplasty.\n  3. Intubation for asthma in the last 12 months\n  4. History of malignancy except non-melanoma skin cancer within the last five years.\n  5. Any chronic medical condition considered by the PI as a contraindication to inclusion in the study including significant cardiovascular disease, diabetes, chronic renal disease, chronic thyroid disease, history of chronic or recurrent infections or immunodeficiency.\n  6. Mental illness or history of substance abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.\n  7. History of smoking: i. Smoking \\>1 time per week in the past year; ii. If ≥40 years old: Smoked ≥15 pack years; iii. If \\\u003C40 years old: Smoked ≥10 pack years; iv. Smoking equivalents of 1 pack cigarettes a day for 1 year: 1 cigar or pipe daily for 1 year; Hookah - 1 session per day for 1 year; E-cigarettes or vapes - 1 cartridge\u002Ftank\u002Fpod per day for 1 year; and active use of smoking\u002Fvaping marijuana, specified as once per week in the last year.\n  8. Allergy\u002Fsensitivity to study drugs or their formulations, including latex\n  9. Unwillingness to use reliable contraception if sexually active (IUD, birth control pills\u002Fpatch, condoms).\n  10. Current participation in an interventional trial in which study administration was administered within the past 60 days or within 5 half-lives of the drug (whichever is greater)\n* Pregnancy, plans to get pregnant or nursing a baby. Female volunteers will be asked to use effective birth control (stable regimen of hormonal contraceptive use for at least 6 months, intrauterine device placement, or tubal ligation for at least 6 months through at least one week after study completion) and will provide a urine sample to test for pregnancy on study days. If the test is positive or the participant has reason to believe she may be pregnant, she will be dismissed from the study. Women who have been amenorrheic for 12 months may participate. Male volunteers will be asked to use condoms for the duration of the study through at least one week after study completion.\n* Usage of the following medications:\n\n  1. Use of daily systemic corticosteroid therapy for asthma control\n  2. Use of any immunomodulatory therapy within the preceding 12 months, including biologics that are approved for asthma.\n  3. Currently receiving allergen immunotherapy\n  4. Use of any immunosuppressant therapy within the preceding 12 months will be reviewed by the study physician.\n* Laboratory: Participants who meet the following criteria will be excluded from study:\n\n  1. Positive QuantiFERON-tuberculosis (TB) gold assay. Cases of indeterminate QuantiFERON-TB test results will require a second specimen to be drawn.\n  2. Baseline absolute neutrophil count (ANC) \\\u003C1.0 x 109\u002FL for participants of African descent, \\\u003C1.5 x 109\u002FL for other participants\n* Allergy\u002Fsensitivity to study drugs or their formulations, including latex.\n* History of anaphylaxis requiring epinephrine treatment\n* Inability or unwillingness of a participant to give written informed consent.\n* Inability or unwillingness to self-administer injectable medication (anakinra or placebo).",{"count":239,"type":23},60,[136],"In this single center, interventional pilot study, 40 participants at high risk for future exacerbation will be randomized to anakinra (v. placebo control) treatment for home administration as part of an asthma action plan (AAP) and monitored through their first moderate asthma exacerbation, triggering treatment dosing over a 26 week period. Key feasibility questions will be assessed in this pilot study to inform trial design and sample size selection for a future multi-site phase II clinical trial testing anakinra as a rescue treatment for moderate asthma exacerbations.",[29,243,244],"Persistent Asthma","Moderate Asthma Exacerbation",[166,246,247,248,249,250,251,243],"Asthma Exacerbation","Anakinra","Kineret","Interleukin-1 Receptor Antagonist","IL-1 receptor blockade","Airway Inflammation","2026-07-13",{"date":254,"type":35},"2026-07-15",{"date":256,"type":23},"2026-11-01",{"date":258,"type":23},"2029-01-01",{"name":260,"class":42},"University of North Carolina, Chapel Hill",{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":18,"minAge":269,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":272,"conditions":273,"keywords":274,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":148},"100640617","quantitative-chest-ct-and-multi-omics-to-distinguish-asthma-from-copd-and-predict-treatment-response-100640617","NCT07602192","Quantitative Chest CT and Multi-Omics to Distinguish Asthma From COPD and Predict Treatment Response","Prospective Multicenter Cohort to Discriminate Asthma Versus Chronic Obstructive Pulmonary Disease and Predict Treatment Response Using Quantitative Chest CT and Multi-Omics","CTOMICS","Inclusion Criteria:\n\n* Age ≥19 years\n* COPD group: post-bronchodilator FEV1\u002FFVC \\\u003C 0.70\n* Asthma group: clinically confirmed diagnosis of asthma by a physician\n* Able to provide voluntary written informed consent\n\nExclusion Criteria:\n\n* Acute exacerbation or active lower respiratory tract infection (e.g., pneumonia) within the past 4 weeks\n* Pregnancy or breastfeeding\n* Inability to undergo chest CT (e.g., poor cooperation or severe medical condition)\n* Refusal to consent to study procedures","19 Years",{"count":271,"type":23},200,"This study aims to improve the diagnosis and treatment prediction of asthma and chronic obstructive pulmonary disease (COPD) by combining quantitative chest computed tomography (CT) imaging with multi-omics data.\n\nAdults with asthma or COPD will be enrolled and undergo routine clinical evaluations, pulmonary function tests, blood tests, and chest CT scans. Additional samples, such as sputum and microbiome specimens, may also be collected. No experimental drugs or devices will be administered as part of this study.\n\nResearchers will analyze CT imaging features together with clinical, laboratory, and biological data to better distinguish asthma from COPD and to identify factors that may predict treatment response. The findings are expected to contribute to more precise and personalized management of chronic airway diseases.",[29,28],[275,276,166,277,278],"Quantitative chest CT","Airway disease","Chronic Obstructive Pulmonary Disease","Treatment response","2026-07-03",{"date":281,"type":35},"2026-07-07",{"date":283,"type":35},"2025-12-22",{"date":285,"type":23},"2027-12-22",{"name":287,"class":42},"Korea University Guro Hospital",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":80,"phases":299,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":148},"100597536","phase-2-phase-iia-trial-in-participants-with-asthma-to-evaluate-impact-of-intranasal-eth47-on-development-of-asthma-related-symptoms-following-rhinovirus-challenge-100597536","NCT07059767","Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge","A Phase IIa, Double-blind, Randomized, Placebo-controlled Trial in Participants With Asthma to Evaluate the Impact of Intranasal ETH47 on the Development of Asthma-related Symptoms Following Rhinovirus Challenge","ETH47-201","Inclusion Criteria:\n\n1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n2. Participants aged ≥18 and ≤65 years at the time of obtaining informed consent.\n3. Diagnosis of clinical asthma (\\>12% reversibility following short acting beta 2 agonist (SABA) treatment or PC20 methacholine challenge of \\\u003C8 mg\u002FmL).\n4. Stable (no change in medication or dose) asthma maintenance therapy with inhaled glucocorticosteroids (ICS) or ICS + long acting beta 2 agonist (LABA) for at least 3 months prior to dosing.\n5. Clinically stable with no exacerbations within 3 months prior to dosing.\n6. Sero-negative test result to RV-A16.\n7. Participants must agree to use contraception methods (if applicable).\n\nExclusion Criteria:\n\n1. Any cold symptom within the last month such as sore throat, sneezing, rhinorrhoea, malaise, nasal obstruction or cough.\n2. Evidence of current allergic rhinitis, including perennial allergic rhinitis, or rhinosinusitis or nasal polyps.\n3. History of or current diagnosis of chronic obstructive pulmonary disease, emphysema, cystic fibrosis or bronchiectasis.\n4. The evidence of any other historic, active or chronic disease following a detailed medical and surgical history which, in the Investigator's judgement, puts the participant at risk due to participation in the trial, may influence the results of the trial, or the participant's ability to participate in the trial. This includes a history of emergency room visits or hospital admissions due to common cold.\n5. Current vaper or smoker, or ex-smoker who stopped within the last 12 months or with a \\>5 year pack history; current vapers may be included if willing to stop prior to Baseline.","65 Years",{"count":298,"type":23},50,[108],"A Phase IIa trial in participants with asthma to evaluate the impact of intranasal ETH47 on the development of asthma-related symptoms following rhinovirus challenge",[29],"2026-06-25",{"date":304,"type":35},"2026-06-26",{"date":306,"type":35},"2025-06-24",{"date":308,"type":23},"2026-06",{"name":310,"class":94},"Ethris GmbH",{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":80,"phases":321,"briefSummary":322,"conditions":323,"keywords":324,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":337,"leadSponsor":339,"locationsCount":43},"100644974","phase-2-a-long-term-study-of-kt-621-administered-orally-to-participants-with-asthma-previously-enrolled-in-a-kt-621-asthma-study-100644974","NCT07677059","A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study","A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study","BREADTH-EXT","Inclusion Criteria:\n\n* Must have completed all visits of the parent study, per its protocol, up to the end of treatment (EoT) visit.\n* Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.\n* Must agree to contraceptive requirements in compliance with the clinical study and local requirements.\n\nExclusion Criteria:\n\n* Must not have experienced any clinically significant change in health status during the parent study, which, in the opinion of the Investigator, would interfere with participant safety, study evaluations, or compliance with study procedures; or otherwise make the participant unsuitable for participation in this study.\n* Must not have developed an AE during the parent study, that in the opinion of the Investigator or of the Sponsor's Medical Monitor, could indicate that continued treatment may present an unreasonable risk for the participant.\n* Must not have met permanent discontinuation criteria and\u002For permanently discontinued study treatment for any reason during the parent study.\n* Must not be a member of the Sponsor or site's investigational team or their immediate family.\n* Must not be unsuitable to enter the study for any other reason, as judged by the Investigator, including potential risk of noncompliance to study procedures.",{"count":320,"type":23},264,[108],"This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.",[29],[325,326,327,328,329,330,331,332],"KT-621","STAT6","stat6 degrader","targeted protein degrader","Phase 2","phase 2b","OLE","LTE","2026-06-24",{"date":335,"type":35},"2026-06-30",{"date":198,"type":23},{"date":338,"type":23},"2028-12",{"name":340,"class":94},"Kymera Therapeutics, Inc.",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":80,"phases":351,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":363,"leadSponsor":365,"locationsCount":148},"100642439","phase-4-evaluation-of-allergen-specific-vaccination-of-dog-allergic-patients-in-swedish-practice-100642439","NCT07651891","Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice","ALLERDOG","Inclusion Criteria\n\nThe subject has provided written informed consent to participate in the study.\n\n* Age 18-50 years.\n* Moderate-to-severe allergic symptoms upon exposure to dogs.\n* Dog allergy confirmed by positive specific IgE.\n* Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC).\n* Female subjects of childbearing potential must use adequate contraception.\n* A negative pregnancy test must be obtained prior to enrolment.\n\nExclusion Criteria\n\n* Pregnancy or breastfeeding.\n* Autoimmune or connective tissue disease.\n* Cardiovascular disease.\n* Hepatic disease.\n* Renal disease.\n* Malignancy.\n* Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis).\n* Chronic obstructive or restrictive lung disease.\n* Treatment with medications that may interfere with the immune response.\n* Previous immunotherapy or chemotherapy.\n* Significant chronic disease.\n* Major metabolic disease.\n* Alcohol or substance abuse.\n* Mental or cognitive incapacity that may impair compliance with study procedures.\n* Known or suspected hypersensitivity to the study product.\n* Suspected or confirmed bacterial infection.\n* Clinically relevant allergy to house dust mite.\n* Current dog ownership.\n* Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate.\n* Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.","50 Years",{"count":350,"type":23},40,[352],"PHASE4","STUDY DESIGN A single-center prospective before-and-after study evaluating the effect of Alutard SQ Dog in 40 men and women with moderate-to-severe dog allergy. Participants will serve as their own controls.\n\nSTUDY OUTLINE\n\nThe study will begin in the fall of 2026 and will be conducted over a one-year period. At baseline, participants will be asked to record their allergic symptoms, and assessments of lung function and nasal airflow will be performed. Blood samples will also be collected.\n\nFollowing the baseline assessments, participants will undergo allergen provocation by entering a facility containing dogs. After a 30-minute exposure to dogs, participants will again be asked to record their allergic symptoms and will undergo the same assessments performed at baseline.\n\nAllergen immunotherapy (AIT) with Alutard SQ Dog will then be initiated according to the standard treatment regimen and continued for one year. At the end of the treatment period, the same provocation procedure and assessments will be repeated. Participants will enter a facility containing dogs, followed by symptom recording and evaluation of lung function, nasal airflow, and relevant laboratory parameters.",[355,29],"Allergic Rhinitis",[357,358,359,166],"AIT","SCIT","Allergic rhinitis",{"date":361,"type":35},"2026-06-29",{"date":121,"type":23},{"date":364,"type":23},"2027-12-01",{"name":366,"class":42},"Karolinska Institutet",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":17,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":80,"phases":377,"briefSummary":378,"conditions":379,"keywords":385,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":43},"100642489","dash-obesity-explainable-ai-for-family-centric-personalized-weight-control-in-adolescents-and-young-adults-with-obesity-and-chronic-conditions-100642489","NCT07638345","DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions","US-based Clinical Sub-study of DASH-Obesity: Explainable AI for Family-Centric Transdiagnostic Personalized Weight Control Across Multiple Conditions","DASH-Obesity","Inclusion Criteria:\n\n* Adult caregiver (aged 18 years or older) of an adolescent or young adult aged 12 to 21 years diagnosed with Type 1 Diabetes (T1D) or asthma.\n* The caregiver is actively involved in the management of the adolescent's or young adult's condition.\n* The adolescent or young adult must meet one of the following criteria:\n* T1D and normal weight (BMI between the 10th and 85th percentile), or\n* T1D and overweight\u002Fobesity (BMI ≥85th percentile), or\n* Asthma and overweight\u002Fobesity (BMI ≥85th percentile).\n* Willingness to participate in the Adhera Caring Digital Program-Obesity (ACDP-O).\n* Access to a smartphone or internet-enabled device compatible with the study application.\n* Willingness to provide self-reported information regarding the adolescent's or young adult's health status, including disease-related and anthropometric measures.\n* For caregivers of participants with T1D, willingness to share continuous glucose monitoring (CGM) information.\n\nExclusion Criteria:\n\n* Severe psychiatric or cognitive conditions that would interfere with participation in the digital intervention.\n* Current participation in another obesity- or chronic disease-related digital health intervention study.\n* Inability or unwillingness to comply with study procedures.\n* Refusal or inability to provide informed consent.",{"count":376,"type":23},280,[161],"This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with overweight\u002Fobesity and chronic conditions, including type 1 diabetes (T1D) and asthma. The intervention combines personalized educational content, wearable-device monitoring, psychometric assessments, and explainable artificial intelligence (AI) to improve mental well-being, quality of life, and adherence to healthy lifestyle behaviors. A total of 280 families will participate in a 3-month intervention with remote monitoring and follow-up assessments.",[380,381,382,383,384,29],"Type 1 Diabetes","T1D","Obesity & Overweight","Obesity Type 2 Diabetes Mellitus","Asthma Acute",[386,380,166,387,388,389,390,391,392,393,394,395],"Pediatric Obesity","Overweight","Digital Health","Artificial Intelligence","Explainable AI","Caregiver Burden","Quality of Life","Mental Well-being","Wearable Devices","Family-Centered Care","2026-06-19",{"date":398,"type":35},"2026-06-23",{"date":400,"type":35},"2025-10-30",{"date":402,"type":23},"2026-09",{"name":404,"class":94},"Adhera Health, Inc.",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":17,"sex":18,"minAge":76,"maxAge":413,"enrollmentInfo":414,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":416,"conditions":417,"keywords":422,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":43},"100642831","breathlessness-perceptions-within-respiratory-diseases-100642831","NCT07648082","Breathlessness Perceptions Within Respiratory Diseases","Exploring Differences in Breathlessness Perceptions Within Respiratory Diseases","BiRD","Inclusion Criteria:\n\n* • Aged 18 or over up to 100\n\n  * Known respiratory diagnosis\\* OR Healthy control\\*\\*\n  * Ongoing symptoms of breathlessness defined as ≥2 MRC dyspnoea scale\n  * Able to communicate in English\n  * Able to attend two study visits\n  * Able to provide written informed consent\n\n    * Known respiratory diagnosis could include, but is not limited to, COPD, Asthma, Bronchiectasis or ILD.\n    * Healthy controls are required to have an absence of a functionally limiting condition such as respiratory, cardiovascular, or musculoskeletal.\n\nExclusion Criteria:\n\n* • Unstable disease or undergoing investigations for unexplained symptoms\n\n  * Undergone a surgery within past six weeks\n  * Contraindications for exercise outlined by ACSM guidelines (Unstable CVD, hypertension etc)\n  * BMI ≥ 35kg\u002Fm2\n  * Unable to communicate in English\n  * Unable to provide written informed consent\n  * Unable to abstain from smoking for 8 hours prior to testing","100 Years",{"count":415,"type":23},75,"Breathlessness is a complex symptom that results in poor quality of life, increased hospitalisations and increased mortality. Breathlessness is influenced by physiological, psychological and functional factors but these are poorly explored. There are also unexplored phenomenon's such as breathing pattern. Therefore, this study aims to understand the influences of physiology, psychology, function and breathing pattern on health related quality of life in those with a respiratory disease compared to healthy controls. This project is a cross-sectional cohort study including those with a known respiratory disease and experiencing breathlessness, compared to non-breathless healthy controls. The investigators will measure your physiology through spirometry (a breathing test that tells us about their lung function), psychology through questionnaires, function through an exercise test and breathing pattern using opto-electrictronic plethysmography (markers are placed on your chest to see how participants breathe while exercising). This will be conducted over two visits. The investigators will recruit participants from clinics at the University Hospitals of Leicester NHS Trust. The investigators are aiming to recruit 50 participants with a respiratory disease and 25 healthy controls. The results of this study will help us understand breathlessness in more detail in order to be able to develop better treatments.",[418,29,419,420,421],"Chronic Obstructive Pulmonary Disease (COPD)","Interstitial Lung Disease (ILD)","Bronchiectasis","Breathing Pattern Disorder",[423,424,425,426,427,428],"Breathlessness","OEP","Cardiopulmonary Exercise Testing","Respiratory diseases","Heart rate variability","Breathing patterns","2026-06-10",{"date":431,"type":35},"2026-06-15",{"date":433,"type":35},"2025-06-06",{"date":435,"type":23},"2026-07-01",{"name":437,"class":42},"University Hospitals, Leicester",{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":17,"sex":18,"minAge":103,"maxAge":4,"enrollmentInfo":444,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":4},"100643772","a-study-to-evaluate-the-diagnostic-performance-of-portable-oscillometry-across-chronic-respiratory-diseases-100643772","NCT07631507","A Study to Evaluate the Diagnostic Performance of Portable Oscillometry Across Chronic Respiratory Diseases","Inclusion Criteria:\n\n* COPD group:\n\n  * Age：≥40\n  * Suspected COPD：COPD-SQ≥16，and no evidence of airflow limitation after bronchodilators\n  * Confirmed COPD：According to the diagnostic criteria in the 2021 Revised Edition of the Chinese Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease and the 2026 GOLD Report, a diagnosis requires the presence of symptoms (such as dyspnea, chronic cough, or sputum production), a history of exposure to risk factors (e.g., smoking, biomass fuels, occupational exposures, or air pollution), evidence of persistent airflow limitation (post-bronchodilator FEV1\u002FFVC \\\u003C 0.70), and the exclusion of alternative diagnoses.\n  * Exclude acute exacerbation within the last month Asthma group：\n  * Age：≥3\n  * Suspected asthma：Patients with chronic respiratory symptoms but no evidence of variable airflow limitation\n  * Confirmed asthma：According to the diagnostic criteria in the 2024 Chinese Guidelines for the Prevention and Treatment of Bronchial Asthma and the 2025 GINA Report, diagnosis requires the presence of recurrent symptoms (such as wheezing, shortness of breath, chest tightness, and cough) that resolve spontaneously or with treatment; evidence of variable airflow limitation (e.g., a positive bronchodilator reversibility test, a positive bronchial provocation test, or an average daily diurnal PEF variability of \\>10% over at least 7 consecutive days); and the exclusion of alternative diagnoses.\n\nHealthy subjects:\n\n* Age ≥ 3 (See Table 1 for details)\n* No respiratory symptoms（cough, expectoration, shortness of breath, wheezing, etc）\n* No history of serious cardiopulmonary or other systemic diseases, especially no history of respiratory diseases and surgery\n* No history of respiratory infection within the past 4 weeks; non-smoker or total lifetime smoking \\\u003C 100 cigarettes\n* No history of occupational exposure to harmful gases or dust, or serious pollution of the work or living environment\n* No abnormalities on chest physical examination\n* No abnormalities were found on chest imaging (X-ray, CT) records within the past year.\n* Body mass index within the normal range (18.5\\~24.9) Confirmed Bronchiectasis Group：\n* Age ≥ 3 years\n* Clinical history consistent with bronchiectasis, confirmed by CT scan\n* No other concurrent or accompanying respiratory diseases at present Confirmed ILD Group：\n* Age ≥ 3 years\n* Fibrotic interstitial lung disease: HRCT scan shows fibrotic lung disease, defined as reticular abnormalities and traction bronchiectasis with or without honeycombing, and the disease extent \\> 10%; or lung tissue biopsy indicates fibrotic interstitial changes\n* No other concurrent or accompanying respiratory diseases at present Confirmed Upper Airway Obstruction Group：\n* Age ≥ 3 years, gender not restricted\n* History of upper airway inflammation, injury, endotracheal intubation or tracheotomy, burns, foreign body aspiration, tracheal tumor, or other conditions that can cause large airway obstruction\n* Clinical manifestations are mainly dyspnea and shortness of breath, which are significantly aggravated after activity, and sometimes symptom exacerbation is related to body position\n* Pulmonary function test shows significant limitation of inspiratory or expiratory flow in the F-V curve, presenting a characteristic plateau pattern\n* At least one of the following evidences: chest CT scan or upper airway three-dimensional reconstruction confirms upper airway stenosis; laryngoscopy or bronchoscopy reveals tracheal\u002Fbronchial wall thickening and\u002For stenosis, intratracheal nodules or neoplasms, tumor infiltration, tracheal mucosal congestion, tracheal cartilage collapse, etc\n\nExclusion Criteria:\n\n* • Contraindications for oscillometry testing and spirometry testing: Oscillometry testing: Severe and intolerable dyspnea, acute exacerbation of respiratory infection, uncontrolled epilepsy, oral or facial diseases or deformities preventing proper latching, tympanic membrane perforation, need for continuous oxygen therapy, indwelling gastric tube, tracheotomy with inability to close the tube, currently undergoing artificial ventilation and unable to temporarily stop the procedure; Spirometry testing: Recent severe cardiovascular disease, epileptic seizures, uncontrolled hypertension, aortic aneurysm, severe hyperthyroidism, heart rate \\>120 bpm, tympanic membrane perforation, other respiratory infectious diseases, etc.;\n\n  * Other respiratory diseases that affect lung function results： such as lung cancer, pneumonia, active pulmonary tuberculosis, pulmonary embolism, etc.; Recent surgical history that affects lung function results, including open-chest surgery, pleural effusion surgery, etc.;\n  * Poor cooperation during basic lung function tests, failing to meet quality control requirements;\n  * Breastfeeding women;\n  * Participants deemed unlikely by the researcher to comply with research procedures and restrictions.",{"count":445,"type":23},4000,"This is a prospective, multicenter, observational cohort study enrolling approximately 4,000 subjects across about 50 centers, including patients with COPD (confirmed and suspected), asthma (confirmed and suspected), bronchiectasis, interstitial lung disease (ILD), upper airway obstruction (UAO), and healthy controls. Participants will undergo standardized clinical assessments, cough search, FENO, ETCO2, impulse oscillometry, spirometry, and\u002For bronchodilator test, and\u002For bronchoprovocation test, and\u002For diffusion capacity test at a single baseline visit, with no investigational intervention or treatment assignment. The primary objective is to evaluate the diagnostic performance of portable impulse oscillometry in Chronic respiratory diseases and to develop an artificial intelligence diagnostic model for COPD based on oscillometry. The study duration per subject is limited to the screening\u002Fbaseline visit, with no follow-up visits planned.",[448,29,449,420,419,450],"COPD","Chronic Respiratory Diseases","Upper Airway Obstruction","2026-06-02",{"date":89,"type":35},{"date":454,"type":23},"2026-07-30",{"date":456,"type":23},"2027-08-30",{"name":458,"class":42},"The First Affiliated Hospital of Guangzhou Medical University",{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":12,"sex":18,"minAge":466,"maxAge":104,"enrollmentInfo":467,"targetDuration":4,"studyType":80,"phases":468,"briefSummary":469,"conditions":470,"keywords":471,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":479,"leadSponsor":481,"locationsCount":43},"100639872","chronic-effects-of-photobiomodulation-with-an-led-vest-on-functional-capacity-inflammatory-markers-and-muscle-perfusion-in-children-with-asthma-100639872","NCT07613671","Chronic Effects of Photobiomodulation With an LED Vest on Functional Capacity, Inflammatory Markers, and Muscle Perfusion in Children With Asthma","Asthma PBM","Critérios de Inclusão: Crianças em idade escolar de 6 a 17 anos Diagnosticado com asma leve a moderada (tratamento farmacológico regular) clinicamente estável Critérios de exclusão:Histórico de exacerbação da asma dentro de 30 dias antes do início do estudo, FAlha no preenchimento dos questionários","6 Years",{"count":239,"type":23},[161],"Asthma is a chronic inflammatory disease of the airways that results in tissue remodeling, airflow limitation, and bronchial hyperresponsiveness. This study aims to evaluate the long-term effects of photobiomodulation using an LED vest in the management of pediatric asthma. It is a randomized clinical trial involving children aged 6 to 17 years diagnosed with mild to moderate asthma, divided into two groups: an intervention group (using a vest with active LEDs) and a control group (using the vest turned off, simulating the intervention without light emission). The methodology includes clinical and functional assessments such as spirometry, the Asthma Control Test (ACT), the GINA questionnaire, and the Incremental Step Test (IST), which measures exercise tolerance. Photobiomodulation through LEDs promotes cellular biostimulation without thermal effects, modulating inflammatory processes and optimizing tissue regeneration. It is expected that the LED vest will contribute to improving pulmonary function, enhancing quality of life, and complementing conventional treatments. This project aims to advance the clinical application of photobiomodulation as an accessible and effective therapeutic alternative for pediatric asthma.",[29],[472,473,217,474,475,61],"pediatric asthma","Photobiomodulation Therapy","Inflammatory Biomarkers","Low-Level Light Therapy (LLLT)","2026-05-28",{"date":451,"type":35},{"date":454,"type":23},{"date":480,"type":23},"2028-01-30",{"name":482,"class":42},"University of Nove de Julho",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":132,"enrollmentInfo":490,"targetDuration":4,"studyType":80,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":4},"100639258","a-study-of-acupuncture-for-treating-asthma-100639258","NCT07611955","A Study of Acupuncture for Treating Asthma","The Effects of Acupuncture on Patients With Chronic Asthma: a Multicenter, Randomized, Three-arm, Sham-controlled Superiority Trial","Inclusion Criteria:\n\n* Meet the diagnostic criteria for asthma, and be in the chronic persistent phase with mild to moderate disease severity, referring to the grading criteria of the Guidelines for the Prevention and Treatment of Asthma (2024 Edition).\n* Aged 18 to 70 years, regardless of gender.\n* Asthma Control Test (ACT) score≤19 points (poorly controlled or very poorly controlled asthma).\n* Maintain a stable asthma treatment regimen for at least 4 weeks before enrollment.\n* Clear thinking and consciousness, coherent responses, able to understand the items of various scales and complete the assessment.\n* Volunteer to participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Complicated with severe mental illnesses (such as uncontrolled schizophrenia, acute phase of bipolar disorder, etc.) or moderate to severe cognitive impairment (such as dementia), resulting in inability to understand the research process or cooperate with efficacy evaluation.\n* A history of substance\u002Falcohol dependence within the past 12 months.\n* Complicated with other physical diseases that may cause depressive symptoms (such as hypothyroidism, chronic pain syndrome, malignant tumors, rheumatoid arthritis, etc.).\n* Received antidepressant drug treatment within the past 6 months.\n* Suffering from other respiratory diseases, such as chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, etc.\n* Complicated with other cancers or relatively severe chronic diseases of the heart, liver, kidneys, etc.\n* Received acupuncture treatment within the past 3 months.\n* Pregnant or lactating women.",{"count":491,"type":23},180,[161],"Asthma is a common chronic respiratory disease with a low clinical control rate, highlighting the need for novel therapeutic strategies. Recurrent asthma attacks emotional symptoms, such as anxiety and depression, etc. On the contrary, symptoms such as anxiety and depression worsen asthma control. Acupuncture is commonly applied as an effective traditional Chinese medical therapy for asthma. Acupoints GV14, BL13 and BL12 are adopted for the intervention of asthma. GV20 and GV29 are selected to improve emotional symptoms including depression. Nevertheless, standardized therapeutic regimens of acupuncture for asthma and its concomitant emotional symptoms are still lacking. 180 patients with mild to moderate asthma will be recruited in this multicenter randomized controlled trial, randomly assigned to the true acupuncture group, sham acupuncture group and usual care group. The primary outcome is the score of the Asthma Control Test (ACT). Secondary outcomes include the Hospital Anxiety and Depression Scale (HADS), Asthma Quality of Life Questionnaire (AQLQ), pulmonary function, and fractional exhaled nitric oxide (FeNO). The superiority of combined acupuncture therapy in improving asthma control, relieving negative emotions, and enhancing quality of life is to be verified in this study, with high quality evidence for acupuncture treatment of asthma thereby to be provided.",[495,29,166],"Asthma Chronic",{"date":497,"type":35},"2026-06-01",{"date":499,"type":23},"2026-05-21",{"date":501,"type":23},"2028-09",{"name":503,"class":42},"Shanghai University of Traditional Chinese Medicine",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":17,"sex":18,"minAge":511,"maxAge":76,"enrollmentInfo":512,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":521,"leadSponsor":523,"locationsCount":43},"100638770","multimodal-assisted-diagnosis-for-pediatric-respiratory-diseases-using-questionnaires-cough-sounds-and-breath-sounds-100638770","NCT07613242","Multimodal Assisted Diagnosis for Pediatric Respiratory Diseases Using Questionnaires, Cough Sounds, and Breath Sounds","A Prospective Observational Study of Multimodal Assisted Diagnosis for Pediatric Respiratory Diseases Using Symptom Questionnaires, Cough Sounds, and Breath Sounds","Inclusion Criteria:\n\nChildren aged 28 days to 18 years, regardless of sex, will be eligible for inclusion. The disease group will include children presenting to the outpatient department, emergency department, or inpatient wards of Shanghai Children's Medical Center with cough, wheezing, fever with respiratory symptoms, nasal congestion, rhinorrhea, sore throat, or other respiratory complaints. Participants should be able to complete the symptom questionnaire, cough sound recording, and breath sound recording, and their guardians must provide informed consent and allow review of relevant medical history and diagnostic information. The healthy control group will include children recruited from routine health examinations or children without respiratory complaints, with no acute respiratory symptoms within the past 4 weeks, no known history of chronic respiratory diseases, no obvious respiratory abnormalities on health assessment or research team review, the ability to complete relevant data collection, and guardian informed consent.\n\nExclusion Criteria:\n\nParticipants will be excluded if they have severe cardiopulmonary malformations, long-term tracheostomy or mechanical ventilation, severe neuromuscular disorders, severe immunodeficiency, or other conditions that may substantially alter cough sound characteristics or affect the clinical presentation of respiratory diseases. Children whose primary diagnosis at the current visit is a non-respiratory disease and who are not suitable for this study will also be excluded. Participants who are unable to complete the symptom questionnaire, or whose cough sound or breath sound recordings remain of insufficient quality after repeated attempts, will not be included or will be excluded from the corresponding modality-specific analysis. Participants with only one unavailable modality may be included in analyses based on the completed modalities but will be excluded from analyses requiring the missing modality. Healthy controls will be excluded from the main control analysis if recent respiratory symptoms, a history of chronic respiratory disease, or other conditions that may affect acoustic features are identified.","28 Days",{"count":513,"type":23},1400,"This study aims to establish a standardized, synchronized data collection system for pediatric symptom questionnaires, cough sounds, and breath sounds, and to construct a multimodal database of pediatric respiratory diseases including both disease cases and healthy controls. Using the final research labels determined by clinicians' diagnoses, health status assessments, and research team review as the reference standard, this study will develop and validate a multimodal assisted diagnostic model for common pediatric respiratory diseases based on symptom questionnaires, cough sounds, and breath sounds. The study will primarily evaluate the diagnostic performance of the model in distinguishing healthy children from children with respiratory diseases, screening for asthma and asthma-related cough, and identifying pneumonia, tracheitis\u002Fbronchitis, upper airway-related diseases, and common causes of chronic cough. It will also assess the incremental value of cough sounds and breath sounds beyond symptom questionnaire information.",[29,516],"Community-Acquired Pneumonia (CAP)","2026-05-23",{"date":519,"type":35},"2026-05-29",{"date":497,"type":23},{"date":522,"type":23},"2029-05-31",{"name":524,"class":42},"Shanghai Children's Medical Center",{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":533,"enrollmentInfo":534,"targetDuration":4,"studyType":80,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":43},"100605311","obstructive-sleep-apnoea-and-difficult-asthma-osada-100605311","NCT07160868","Obstructive Sleep Apnoea and Difficult Asthma (OSADA)","Open-label Randomized Controlled Trial Investigating the Relationship Between Obstructive Sleep Apnoea and Difficult Asthma","OSADA","Inclusion Criteria:\n\n* Patients must have a clinical diagnosis of asthma with supportive objective diagnostics including but not limited to, variable airflow obstruction, bronchial-hyper responsiveness and demonstrable eosinophilic inflammation via fractional exhaled nitric oxide or peripheral eosinophilia\n* Patients receiving step 4 or step 5 of 'The Global Initiative for Asthma' (GINA) treatment guidelines will be selected\n* Between the ages of 18 to 90 years of age\n\nExclusion Criteria:\n\n* Patients with previous sleep study investigations\n* Excessive daytime sleepiness; ESS \\>17\n* Previous diagnosis of a sleep disorder\n* Resting hypoxaemia or need for long-term oxygen therapy\n* Inability to provide informed consent","90 Years",{"count":535,"type":23},80,[161],"The OSADA (Obstructive Sleep Apnoea in Difficult Asthma) trial is an open-label, randomized control trial investigating the impact of diagnosing and treating obstructive sleep apnoea (OSA) on a asthma control in patients with difficult-to-control asthma.\n\nParticipants will undergo home-based sleep studies to assess for OSA and are then allocated to one of three arms: 1) Patients with OSA treated with CPAP (intervention group), 2) Patients with OSA not treated for OSA (control group) and 3) Patients without OSA (reference group).\n\nThe primary objective is to evaluate whether treating OSA improves asthma control, symptom burden, and quality of life compared to untreated OSA and to patients without OSA. Secondary outcomes include exacerbation rates, sleep quality, and healthcare utilization.\n\nThis trial aims to clarify the contribution of OSA to poor asthma control and the potential benefits of integrated sleep and respiratory care in this complex population.",[29,539,540],"OSA - Obstructive Sleep Apnea","CPAP Treatment","2026-05-20",{"date":543,"type":35},"2026-05-26",{"date":545,"type":35},"2025-09-01",{"date":547,"type":23},"2026-05-22",{"name":549,"class":42},"St. James's Hospital, Ireland",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":558,"enrollmentInfo":559,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":561,"conditions":562,"keywords":563,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":43},"100612461","a-study-to-understand-the-accuracy-of-a-new-breathing-device-compared-to-standard-testing-for-asthma-and-copd-100612461","NCT07253883","A Study to Understand the Accuracy of a New Breathing Device Compared to Standard Testing for Asthma and COPD","A Diagnostic Accuracy Study: N-Tidal Assessment for Respiratory Diagnosis Compared to Using Standard Testing","STARDUST","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Referred for respiratory diagnostic testing with a clinical suspicion of asthma or COPD\n* Participant is willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Referred for respiratory diagnostic testing for a condition other than asthma or COPD, with no mention in the referral of a clinical suspicion of COPD or asthma\n* Participants who, in the opinion of the chief investigator, or their delegate, are unlikely to comply with the requirements of the study\n* Inability to give written informed consent\n* Participants who are acutely unwell\n* Patients unable to breathe through their mouths e.g. tracheostomy patients","110 Years",{"count":560,"type":23},1200,"The diagnosis of either asthma or chronic obstructive pulmonary disease (COPD) is currently based on a combination of symptoms, different lung tests and sometimes a 'trial by treatment'. Both COPD and Asthma tests currently include forced breathing using a test known as spirometry which can be difficult and uncomfortable for people to perform and needs expert interpretation. Asthma can require multiple tests in sequence which can make the process of diagnosis long and inconvenient for patients. In the UK, there have been challenges providing enough testing for COPD and asthma, in part because the tests are challenging to provide in the community to everyone who needs one.\n\nThe STARDUST study aims to test and develop new ways of diagnosing asthma and COPD that are quick, accurate and easy for patient and healthcare professionals to perform. People who have been referred for routine lung testing will breathe normally in and out into a handheld device called the N-Tidal Handset for 75 seconds. This device measures how the level of carbon dioxide (CO2) changes in the breath as people breath through it. The information gathered on the N-Tidal Handsets, called breath records or capnograms, will not be used to alter the diagnosis of any participants in the study.\n\nAfter the capnograms have been collected, the research team will test 'algorithms' that have been developed using artificial intelligence, to see if they can accurately identify the correct diagnosis. Information collected in the study will also be used to make improvements in these algorithms.\n\nIf confirmed to be accurate, these algorithms could be used in clinical practice to help healthcare professionals make faster, more accessible and accurate diagnoses, especially in settings like GP clinics in the community where access to specialist tests may be limited.",[29,28],[166,448,564,565,566],"End tidal CO2","Diagnostics","Machine learning","2026-04-21",{"date":569,"type":35},"2026-04-24",{"date":571,"type":23},"2026-04-01",{"date":573,"type":23},"2027-05-19",{"name":575,"class":42},"Liverpool Heart and Chest Hospital NHS Foundation Trust",{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":582,"enrollmentInfo":583,"targetDuration":4,"studyType":80,"phases":585,"briefSummary":586,"conditions":587,"keywords":588,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":43},"100633681","comparative-effects-of-alternative-nostril-breathing-versus-buteyko-breathing-on-control-pause-dyspnea-and-pulmonary-function-in-patients-with-bronchial-asthma-100633681","NCT07529847","Comparative Effects of Alternative Nostril Breathing Versus Buteyko Breathing on Control Pause, Dyspnea and Pulmonary Function in Patients With Bronchial Asthma","Inclusion Criteria:\n\n* Age between 18-45 years\n* Both genders (male and female)\n* Grade 1-3 on mMRC scale of dyspnea\n* Asthma severity classes- intermediate,mild persistent and moderate persistent asthma (acc. to NAEPP National Asthma Education and Prevention Program guidlines 2020)\n\nExclusion Criteria:\n\n* Patients having acute exerbation of COPD\u002Fstatus asthmaticus\n* Patients diagnosed with acute infection\n* Patients unable to follow command and instructions\n* Asthma patients with \\>40sec control pause duration","45 Years",{"count":584,"type":23},46,[161],"Bronchial asthma is a chronic inflmmatory airway disease characterized by recurrent episodes of dyspnea, wheezing, and airflow limitation.\n\nDysfunctional breathing pattern and chronic hyperventilation",[29],[589,590,591,592,593,594],"Bronchial asthma","alternative nostril breathing","buteyko breathing","dyspnea","pulmonary function","asthma control","2026-04-07",{"date":597,"type":35},"2026-04-14",{"date":599,"type":35},"2026-02-28",{"date":601,"type":23},"2026-05-15",{"name":603,"class":42},"Foundation University Islamabad",{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":80,"phases":614,"briefSummary":615,"conditions":616,"keywords":622,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":43},"100632804","somatic-health-screening-for-adults-in-outpatient-psychiatric-care-in-denmark-somascreen-100632804","NCT07518446","Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)","Somatic Screening in the Capital Region Mental Health Service in Denmark (SomaScreen) - Study Protocol for a Quasi-experimental Controlled Intervention Study With a Matched Cohort","SomaScreen","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Referred to FACT or OPUS psychiatric outpatient clinics in the Capital Region of Denmark.\n* Starting a new outpatient treatment episode in FACT or OPUS.\n* Diagnosed with psychotic or affective disorders (ICD-10 F20-F39), including those with comorbid substance use disorders (F10-F19).\n\nExclusion Criteria:\n\n* Individuals younger than 18 years.\n* Patients in geriatric outpatient clinics.\n* Individuals not in the target diagnosis group (i.e., without psychotic or affective disorders, F20-F39).\n* Individuals who do not meet the inclusion criteria above.",{"count":613,"type":23},2800,[161],"People with severe mental illness have a substantially increased risk of undiagnosed and insufficiently treated somatic disease. Somatic Screening in the Capital Region Mental Health Service in Denmark (SomaScreen) is a service-level intervention implemented in psychiatric outpatient clinics in the Capital Region of Denmark to improve the detection and follow-up of somatic disease among patients with psychotic and affective disorders.\n\nThis study evaluates whether integrating structured somatic screening into mental health services leads to improved identification and management of somatic disease compared with care as usual. Using a quasi-experimental controlled design with a matched cohort, outcomes among patients exposed to the SomaScreen intervention are compared with those of patients receiving usual care in comparable psychiatric outpatient clinics outside the Capital Region.",[617,618,29,418,619,620,621],"Atrial Fibrillation (AF)","Heart Failure","Diabetes","Cancer","Psychiatric Patients, Serious Medical Illness",[623,624,625,626,627,628],"Somatic screening","Early diagnosis","Continuity of patient care","Cohort studies","Mental disorders","Health status disparities",{"date":630,"type":35},"2026-04-08",{"date":632,"type":35},"2024-09-01",{"date":634,"type":23},"2028-10-30",{"name":636,"class":42},"Amager Hospital",{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":641,"acronym":642,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":646,"conditions":647,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":43},"100620337","body-composition-related-evaluation-of-airway-tone-and-hyper-reactivity-using-oscillometry-100620337","NCT07356310","Body Composition Related Evaluation of Airway Tone and Hyper-rEactivity Using Oscillometry","BREATH-OSC","Inclusion Criteria:\n\n* Willingness to perform breathing test\n* Must be able to speak and understand English\n* Referred for Methacholine Challenge Test\n\nExclusion Criteria:\n\n* Unable to provide consent or perform oscillometry test",{"count":645,"type":23},100,"This study will determine if airway resistance to airflow and pressure, measured by Oscillometry, is associated with abnormal findings on methacholine challenge testing and whether these findings are associated with body habitus,",[648,649,29,650],"Breathing","Lung Function Decreased","Obesity",{"date":652,"type":35},"2026-04-13",{"date":654,"type":35},"2026-02-17",{"date":656,"type":23},"2027-11-01",{"name":658,"class":42},"University of Rochester",{"id":660,"slug":661,"hasResults":12,"nctId":662,"briefTitle":663,"officialTitle":664,"acronym":4,"eligibilityCriteria":665,"healthyVolunteers":17,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":666,"targetDuration":4,"studyType":80,"phases":667,"briefSummary":668,"conditions":669,"keywords":671,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":679,"lastUpdatePostDateStruct":680,"startDateStruct":682,"completionDateStruct":683,"leadSponsor":684,"locationsCount":43},"100631976","can-astaxanthin-help-manage-asthma-in-polluted-areas-100631976","NCT07507682","Can Astaxanthin Help Manage Asthma in POlluted Areas?","Investigating Astaxanthin as a Novel Therapy for Asthma Management in Polluted Environments","Inclusion Criteria:\n\n* Adults 18+ y\n* Confirmed clinical diagnosis of mild-to-moderate asthma, defined as:\n\n  * A physician diagnosed asthma condition consistent with BTS\u002FNICE\u002FSIGN (2024)\n  * Asthma managed at GINA (2024) step 1-3 therapy level, with stable maintenance treatment for ≥4 weeks prior to enrolment\n  * No asthma exacerbation requiring systemic corticosteroids within the preceding 6-8 weeks\n\n(those with suspected Asthma will be invited to a familiarisation and eligibility session where they will have clinical investigations to assess for asthma and thus be included or excluded)\n\n* Ability to demonstrate acceptable and repeatable spirometry in accordance with ATS\u002FERS standards\n* Willing to refrain from antioxidant and anti-inflammatory supplementation (e.g. Omega-3, turmeric, NSAID supplements) for the duration of the study\n* Not consuming high dietary ASTX sources (e.g., frequent salmonid or crustacean intake), assessed at screening\n* non-smoking and non-vaping\n* Able and willing to take daily study capsules and attend all required visits\n* Able and willing to complete home monitoring, including peak flow, air-quality monitoring, and questionnaires\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Current smokers or vapers which is associated with chronic airway remodelling, reduce hyperresponsiveness to bronchodilators, and increased neutrophilic inflammation, which can obscure the true effects of asthma-target interventions\n* Respiratory tract infection within the preceding 4 weeks\n* Pregnant or lactating individuals\n* Presence of significant co-morbidities, including CVD or autoimmune or systemic inflammatory diseases\n* Renal or gastrointestinal disorders that may affect astaxanthin absorption and metabolism\n* Known allergy or hypersensitivity to ASTX or any components of the study supplement\n* History of current evidence of alcohol or substance abuse\n* Participation in another interventional drug or supplement study within the preceding 3 months\n* Use of medicines with a narrow therapeutic index where supplement interactions may pose risk (e.g., ciclosporin\u002Ftacrolimus, warfarin), assessed by investigator\n* Other significant chronic respiratory disease (e.g., COPD, bronchiectasis)",{"count":7,"type":23},[161],"This study will test whether astaxanthin, a naturally occurring antioxidant supplement, can improve lung function, reduce airway inflammation, and improve asthma control in adults with mild-to-moderate asthma. Participants will receive astaxanthin and placebo in random order in a double-blind crossover design. Each treatment period lasts 4 weeks and is separated by a 3-week washout period. The study also measures indoor and personal air pollution exposure to examine whether pollution influences asthma symptoms, airway responsiveness, and response to treatment. Exploratory thoracic bioelectrical impedance spectroscopy will be assessed alongside standard respiratory tests.",[29,251,670],"Airway Hyperresponsiveness",[672,673,674,675,676,677,678],"Astaxanthin","Mild-to-Moderate Asthma","Air Pollution","FeNO","Hypertonic Saline Challenge","Impulse Oscillometry","Thoracic Bioelectrical Impedance Spectroscopy","2026-03-27",{"date":681,"type":35},"2026-04-02",{"date":601,"type":23},{"date":143,"type":23},{"name":685,"class":42},"Middlesex University"]